Clinical Trial Detail

NCT ID NCT01492673
Title Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing's Sarcoma and Neuroblastoma
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Memorial Sloan-Kettering Cancer Center
Indications

Ewing sarcoma of bone

extraosseous Ewing sarcoma

neuroblastoma

Therapies

Bevacizumab + Cyclophosphamide + Topotecan

Age Groups: adult child

No variant requirements are available.